Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06046248
PHASE2
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Sponsor: Northside Hospital, Inc.
View on ClinicalTrials.gov
Summary
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Official title: Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2024-01-29
Completion Date
2027-12-31
Last Updated
2025-10-30
Healthy Volunteers
No
Conditions
Interventions
DRUG
Belumosudil
200mg PO QD x 24 cycles (28-day cycle)
DRUG
Rituximab
375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
Locations (1)
Northside Hospital
Atlanta, Georgia, United States